Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
暂无分享,去创建一个
Ting Zhou | Amedeo Caflisch | Danzhi Huang | Karine Lafleur | Cristina Nevado | A. Caflisch | Danzhi Huang | C. Nevado | K. Lafleur | Ting Zhou | D. Huang
[1] Ralph G Zinner,et al. Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer , 2005, Clinical Cancer Research.
[2] K. Shokat,et al. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Fairlie,et al. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. , 2007, Drug discovery today.
[4] H. Heinzer,et al. Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma , 2007, Oncology Research and Treatment.
[5] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[6] A. Caflisch,et al. Structure‐based tailoring of compound libraries for high‐throughput screening: Discovery of novel EphB4 kinase inhibitors , 2008, Proteins.
[7] O. Issinger,et al. Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate. , 2005, Journal of molecular biology.
[8] G. Giaccone,et al. Tyrosine kinase inhibitors in lung cancer. , 2012, Hematology/oncology clinics of North America.
[9] L. Tong,et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.
[10] F. Sheinerman,et al. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. , 2005, Journal of molecular biology.
[11] Cherrington,et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.
[12] Britt-Marie Swahn,et al. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. , 2005, Bioorganic & medicinal chemistry letters.
[13] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[14] Kevan M Shokat,et al. Targeting the gatekeeper residue in phosphoinositide 3-kinases. , 2005, Bioorganic & medicinal chemistry.
[15] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[16] Katrin Kinkel,et al. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. , 2008, Journal of medicinal chemistry.
[17] N. Brooijmans,et al. Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies , 2009 .
[18] Anthony C. Bishop,et al. Structural basis for selective inhibition of Src family kinases by PP1. , 1999, Chemistry & biology.
[19] M Levitt,et al. Comprehensive assessment of automatic structural alignment against a manual standard, the scop classification of proteins , 1998, Protein science : a publication of the Protein Society.
[20] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[21] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[22] M. Fleming,et al. The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity* , 2006, Journal of Biological Chemistry.
[23] P. Zarrinkar,et al. High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.
[24] Ricardo M Biondi,et al. Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. , 2004, Trends in biochemical sciences.
[25] D. Zaller,et al. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. , 2003 .
[26] M. Vieth,et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.
[27] Anna Vulpetti,et al. Sequence and structural analysis of kinase ATP pocket residues. , 2004, Farmaco.
[28] Radha Akella,et al. Substrate and docking interactions in serine/threonine protein kinases. , 2007, Chemical reviews.
[29] S. Henikoff,et al. Amino acid substitution matrices. , 2000, Advances in protein chemistry.
[30] J. Lisnock,et al. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. , 2003, Chemistry & biology.
[31] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[32] P. Carmeliet,et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation , 2008, British Journal of Cancer.
[33] T. Hunter,et al. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[35] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[36] N. Gray,et al. Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.
[37] J. Murray,et al. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. , 2006, Bioorganic & medicinal chemistry letters.
[38] Mark E. J. Newman,et al. The Structure and Function of Complex Networks , 2003, SIAM Rev..
[39] A. Ullrich,et al. Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors* , 2003, The Journal of Biological Chemistry.
[40] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[41] R J Fletterick,et al. Structural clues to prion replication. , 1994, Science.
[42] M. Vieth,et al. Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.
[43] Edward M. Reingold,et al. Graph drawing by force‐directed placement , 1991, Softw. Pract. Exp..
[44] S. Henikoff,et al. Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[45] D. Zaller,et al. Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity , 2003, Nature Structural Biology.
[46] Jeffrey Jie-Lou Liao,et al. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.
[47] Xi Zhang,et al. Molecular basis for specificity in the druggable kinome : sequence-based analysis , 2007 .
[48] O. H. Chan,et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. , 2000, Journal of medicinal chemistry.
[49] Bert Vogelstein,et al. Combinatorial chemoprevention of intestinal neoplasia , 2000, Nature Medicine.
[50] Jon Read,et al. Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. , 2008, Bioorganic & medicinal chemistry letters.
[51] S. Knapp,et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.
[52] John Kuriyan,et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.
[53] P. Cohen,et al. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. , 1998, Chemistry & biology.
[54] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[55] A. Caflisch,et al. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). , 2009, Journal of medicinal chemistry.
[56] Susan Quinn,et al. Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer , 2008, Clinical Cancer Research.
[57] Li Xing,et al. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. , 2009, Biochemistry.
[58] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[59] C. Sawyers,et al. Targeted cancer therapy , 2004, Nature.
[60] P. Furet,et al. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.
[61] E. de Moliner,et al. The Replacement of ATP by the Competitive Inhibitor Emodin Induces Conformational Modifications in the Catalytic Site of Protein Kinase CK2* , 2000, The Journal of Biological Chemistry.
[62] C. Mol,et al. Switching on kinases: oncogenic activation of BRAF and the PDGFR family , 2004, Nature Reviews Cancer.
[63] Xin Huang,et al. Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer , 2007, Clinical Cancer Research.
[64] Elizabeth J. Goldsmith,et al. Substrate and Docking Interactions in Serine/Threonine Protein Kinases , 2008 .
[65] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[66] Gavin Harper,et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[67] B. Druker,et al. Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib , 2003, Pharmacological Reviews.
[68] Chao Zhang,et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. , 2007, Nature chemical biology.